Fenix Pharma acquires Wave Pharma: new opportunities in oncology.
Fenix is the first pharmaceutical cooperative in Italy: revenue and objectives on the rise.
**Fenix Pharma, through its subsidiary Fenix Life, announces the acquisition of Wave Pharma, a pharmaceutical company focused on oncology. Wave owns and promotes drugs for the treatment of breast cancer in postmenopausal women.** "Eleven years after the founding of Fenix Pharma," comments CEO Salvatore Manfredi, "we are excited to embark on a growth journey by completing the acquisition of Wave and welcoming their team of professionals to Fenix. This acquisition will allow us to enter a field where we believe our approach, based on cooperative values and principles, can contribute to supporting the medical community in managing cancer patients and the therapies they require. We will strengthen our presence in the field and our commitment to providing the oncology treatments patients need." Thanks to this new step, Fenix Pharma continues its growth strategies in specialized therapeutic areas and consolidates a total network of 100 people, including 91 medical sales representatives and 9 Area Managers.
**The story of Fenix Pharma begins in the summer of 2011, when the pharmaceutical multinational Warner Chilcott suddenly decided to exit the European market, effectively shutting down the company and, most importantly, leaving its employees without jobs.** In the same year, from the ashes of that closure, thanks to the foresight of some of those employees, Fenix Pharma was born with the goal of uniting forces to pursue a shared project of life and work. Over the course of more than eleven years, Fenix Pharma has grown and successfully established itself in the pharmaceutical market, driven by the innovative strength of its products and the cooperative spirit of the people who joined the project. Today, Fenix Pharma represents the first and only pharmaceutical cooperative in Italy, with a sales force of about one hundred people. Fenix Pharma operates in the distribution of pharmaceuticals, medical devices, and dietary supplements, across various therapeutic areas (**gastroenterology, osteoarticular, otorhinolaryngology, urogynecology**), distinguishing itself for its high-quality product standards and its commitment to protecting the buyer. These values have enabled Fenix Pharma to achieve significant results year after year, looking to the future with hope and enthusiasm. As evidenced by the results: thanks to the adoption of a hybrid business model that includes both the development of proprietary products and products promoted on behalf of a long-term partner, the company has experienced consistent growth, reaching a turnover of over 10 million euros.
**The acquisition of Wave Pharma is part of the milestones the company has set for itself, including the increase of pharmaceutical properties and the expansion of its offering of dietary supplements and medical devices, with the goal of launching at least two products per year in each therapeutic area.**
English 
Italian